Form 4 for CALC CalciMedica, Inc.
Accepted 2024-01-25 00:00:00 ET · period of report 2024-01-23 · accession 0001415889-24-001831 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMI | 2024-01-25 | 2024-01-23 | CALC | MIDDLETON FRED A | Dir, 10% | P - Purchase | $3.70 | +679.4K | 30.3K | New | +$2.51M |
| DMI | 2024-01-25 | 2024-01-23 | CALC | MIDDLETON FRED A | Dir, 10% | P - Purchase | $0.13 | +679.4K | 121.7K | New | +$88.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-23 | P | A | 144,676 | $3.70 | 727,433 | I By Sanderling Venture Partners VI Co-Investment Fund, L.P. | — | — | (F3) The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. |
| 2 | Common | Common Stock | 2024-01-23 | P | A | 194,472 | $3.70 | 435,148 | I By Sanderling Ventures VII, L.P. | — | — | (F4) The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the securities of the Issuer held by Sanderling Ventures VII, LP ("SVP VII, LP", together with Sanderling Ventures Management VII, Sanderling Ventures VII (Canada), L.P. and Sanderling Ventures VII Annex Fund, L.P., the "Sanderling VII Shares"). The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. |
| 3 | Common | Common Stock | 2024-01-23 | P | A | 13,184 | $3.70 | 27,609 | I By Sanderling Ventures VII Annex Fund, L.P. | — | — | (F4) The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the securities of the Issuer held by Sanderling Ventures VII, LP ("SVP VII, LP", together with Sanderling Ventures Management VII, Sanderling Ventures VII (Canada), L.P. and Sanderling Ventures VII Annex Fund, L.P., the "Sanderling VII Shares"). The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. |
| 4 | Common | Common Stock | 2024-01-23 | P | A | 3,920 | $3.70 | 21,602 | I By Sanderling Ventures Management VI | — | — | (F3) The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. |
| 5 | Common | Common Stock | 2024-01-23 | P | A | 243,356 | $3.70 | 946,744 | I By Sanderling Venture Partners VI, LP | — | — | (F2) The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the securities of the Issuer held by Sanderling Venture Partners VI, LP ("SVP VI, LP", together with Sanderling Venture Partners VI Co-Investment Fund, L.P., Sanderling VI Beteiligungs GmbH & Co. KG, Sanderling Ventures Management VI and Sanderling VI Limited Partnership (the "Sanderling VI Shares"). The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. |
| 6 | Common | Common Stock | 2024-01-23 | P | A | 51,032 | $3.70 | 114,260 | I By Sanderling Ventures VII (Canada), L.P. | — | — | (F5) The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. |
| 7 | Common | Common Stock | 2024-01-23 | P | A | 28,744 | $3.70 | 30,292 | I By Sanderling Ventures Management VII | — | — | (F5) The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. |
| 8 | Derivative | Warrant | 2024-01-23 | P | A | 72,338 | $0.13 | 72,338 | I By Sanderling Venture Partners VI Co-Investment Fund, L.P. | $7.15 · 2024-01-23 to 2026-12-31 | 72,338 Common Stock | (F3) The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. (F8) The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter. |
| 9 | Derivative | Warrant | 2024-01-23 | P | A | 14,372 | $0.13 | 14,372 | I By Sanderling Ventures Management VII | $7.15 · 2024-01-23 to 2026-12-31 | 14,372 Common Stock | (F5) The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. (F8) The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter. |
| 10 | Derivative | Warrant | 2024-01-23 | P | A | 14,372 | $0.13 | 14,372 | I By Sanderling Ventures Management VII | $5.36 · 2024-01-23 to 2024-12-31 | 14,372 Common Stock | (F5) The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. (F7) The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter. |
| 11 | Derivative | Warrant | 2024-01-23 | P | A | 1,960 | $0.13 | 1,960 | I By Sanderling Ventures Management VI | $7.15 · 2024-01-23 to 2026-12-31 | 1,960 Common Stock | (F3) The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. (F8) The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter. |
| 12 | Derivative | Warrant | 2024-01-23 | P | A | 1,960 | $0.13 | 1,960 | I By Sanderling Ventures Management VI | $5.36 · 2024-01-23 to 2024-12-31 | 1,960 Common Stock | (F3) The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. (F7) The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter. |
| 13 | Derivative | Warrant | 2024-01-23 | P | A | 6,592 | $0.13 | 6,592 | I By Sanderling Ventures VII Annex Fund, L.P. | $7.15 · 2024-01-23 to 2026-12-31 | 6,592 Common Stock | (F5) The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. (F8) The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter. |
| 14 | Derivative | Warrant | 2024-01-23 | P | A | 6,592 | $0.13 | 6,592 | I By Sanderling Ventures VII Annex Fund, L.P. | $5.36 · 2024-01-23 to 2024-12-31 | 6,592 Common Stock | (F5) The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. (F7) The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter. |
| 15 | Derivative | Warrant | 2024-01-23 | P | A | 25,516 | $0.13 | 25,516 | I By Sanderling Ventures VII (Canada), L.P. | $7.15 · 2024-01-23 to 2026-12-31 | 25,516 Common Stock | (F5) The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. (F8) The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter. |
| 16 | Derivative | Warrant | 2024-01-23 | P | A | 25,516 | $0.13 | 25,516 | I By Sanderling Ventures VII (Canada), L.P. | $5.36 · 2024-01-23 to 2024-12-31 | 25,516 Common Stock | (F5) The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. (F7) The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter. |
| 17 | Derivative | Warrant | 2024-01-23 | P | A | 97,236 | $0.13 | 97,236 | I By Sanderling Ventures VII, L.P. | $7.15 · 2024-01-23 to 2026-12-31 | 97,236 Common Stock | (F5) The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. (F8) The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter. |
| 18 | Derivative | Warrant | 2024-01-23 | P | A | 97,236 | $0.13 | 97,236 | I By Sanderling Ventures VII, L.P. | $5.36 · 2024-01-23 to 2024-12-31 | 97,236 Common Stock | (F5) The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. (F7) The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter. |
| 19 | Derivative | Warrant | 2024-01-23 | P | A | 72,338 | $0.13 | 72,338 | I By Sanderling Venture Partners VI Co-Investment Fund, L.P. | $5.36 · 2024-01-23 to 2024-12-31 | 72,338 Common Stock | (F3) The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. (F7) The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter. |
| 20 | Derivative | Warrant | 2024-01-23 | P | A | 121,678 | $0.13 | 121,678 | I By Sanderling Venture Partners VI, LP | $7.15 · 2024-01-23 to 2026-12-31 | 121,678 Common Stock | (F3) The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. (F8) The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter. |
| 21 | Derivative | Warrant | 2024-01-23 | P | A | 121,678 | $0.13 | 121,678 | I By Sanderling Venture Partners VI, LP | $5.36 · 2024-01-23 to 2024-12-31 | 121,678 Common Stock | (F3) The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. (F7) The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter. |